Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-29
2008-01-29
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S557000
Reexamination Certificate
active
10746698
ABSTRACT:
The invention is directed to a series of novel crystalline olanzapine forms, in particular hydrated and solvated crystalline forms of olanzapine, methods of use in pharmaceutical compositions, and method of treating psychiatric disorders using the crystalline forms. One series of the crystalline forms are hydrates, i.e. water containing crystals, wherein water may be present in a ratio of about 2:1.5 to a ratio of about 1:3 olanzapine:water, while another includes solvates such as an isobutanol solvate. The olanzapine crystalline forms include Forms H, G, Y, X, K, S, Q, Z, and J.
REFERENCES:
patent: 5229382 (1993-07-01), Chakrabarti et al.
patent: 5631250 (1997-05-01), Bunnell et al.
patent: 5637584 (1997-06-01), Larsen
patent: 5703232 (1997-12-01), Bunnell et al.
patent: 5736541 (1998-04-01), Bunnell et al.
patent: 6008216 (1999-12-01), Chakrabarti et al.
patent: 6020487 (2000-02-01), Bunnell et al.
patent: 6169084 (2001-01-01), Bunnell et al.
patent: 6251895 (2001-06-01), Larsen et al.
patent: 6348458 (2002-02-01), Hamied et al.
patent: 6740753 (2004-05-01), Davies et al.
patent: 6906062 (2005-06-01), Chhabada et al.
patent: 7022698 (2006-04-01), Hamied et al.
patent: 2004/0048854 (2004-03-01), Patel et al.
patent: 2004/0067936 (2004-04-01), Reguri et al.
patent: 2005/0153954 (2005-07-01), Reguri et al.
patent: 2005/0239772 (2005-10-01), Piechaczek et al.
patent: 2005/0267099 (2005-12-01), Keltjens et al.
patent: 2005/0272720 (2005-12-01), Keltjens
patent: 2005/0272721 (2005-12-01), Keltjens
patent: 2006/0040920 (2006-02-01), Kotar Jordon et al.
patent: 0 733 634 (1996-09-01), None
patent: 0 733 635 (2001-08-01), None
patent: 0 831 098 (2001-11-01), None
patent: WO 02/18390 (2002-03-01), None
patent: WO 02/060906 (2002-08-01), None
patent: WO 03/037903 (2003-05-01), None
patent: WO 03/091260 (2003-11-01), None
patent: WO 03/097650 (2003-11-01), None
patent: WO 2004/000847 (2003-12-01), None
patent: WO 2004/056833 (2004-07-01), None
patent: WO 2004/065390 (2004-08-01), None
patent: WO 2004/113346 (2004-12-01), None
patent: WO 2005/080401 (2005-09-01), None
patent: WO 2005/085256 (2005-09-01), None
patent: WO 2005/090359 (2005-09-01), None
patent: WO 2005/107375 (2005-11-01), None
patent: WO 2006/006180 (2006-01-01), None
patent: WO 2006/006185 (2006-01-01), None
patent: WO 2006/010620 (2006-02-01), None
patent: WO 2006/013435 (2006-02-01), None
patent: WO 2006/025065 (2006-03-01), None
patent: WO 2006/027800 (2006-03-01), None
patent: WO 2006/030300 (2006-03-01), None
Polla, G.I, et al., “Thermal behaviour and stability in Olanzapine”, International Journal of Pharmaceutics, v. 301 (2005) pp. 33-40.
Reutzel-Edens et al.,Anhydrates and Hydrates of Olanzapine: Crystallization, Solid-State Characterization, and Structural Relationship, “Crystal Growth and Design”, 2003, 3, 897-907.
Aronhime Judith
Diller Dov
Dolitzky Ben Zion
Coleman Brenda
Kenyon & Kenyon LLP
Teva Pharmaceutical Industries Ltd.
LandOfFree
Crystal forms, methods for their preparation and method for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystal forms, methods for their preparation and method for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystal forms, methods for their preparation and method for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3937639